The mechanisms responsible for resistance to immune checkpoint inhibition are not fully defined, but treatment responsiveness has been associated with the presence of an inflamed tumor microenvironment [5], which is characterized by infiltrating T cells [6] and the expression of interferon (IFN)-associated genes [7, 8]. The gene discussed is IFNA1; the disease is neoplasm.